N. BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced Phase 1 data for its novel heart failure Positron Emission Tomography (PET) imaging agent, LMI 1195, which is in development for the evaluation of patients at risk of heart failure or sudden cardiac death. The preliminary data showed that LMI 1195 can render high-quality, well-defined images of the cardiac autonomic nervous system, which helps regulate the electrical activity of the heart and its ability to contract1. In addition to the high and uniform myocardial uptake, the radiotracer cleared quickly from the blood and had a favorable safety and dosimetry profile.
